Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4170 | MCL1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 2.51e-05 | 1.40e+00 | -0.2247 |
4170 | MCL1 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 2.98e-09 | 9.98e-01 | -0.1433 |
4170 | MCL1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 3.17e-09 | 8.48e-01 | -0.1833 |
4170 | MCL1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 6.57e-10 | 1.06e+00 | -0.23 |
4170 | MCL1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 5.83e-09 | 9.64e-01 | -0.23 |
4170 | MCL1 | 047563_1562-all-cells | Human | Prostate | BPH | 1.95e-15 | -1.55e-01 | 0.0791 |
4170 | MCL1 | 048752_1579-all-cells | Human | Prostate | BPH | 2.72e-06 | 3.44e-01 | 0.1008 |
4170 | MCL1 | Dong_P1 | Human | Prostate | Tumor | 1.49e-35 | 2.14e-01 | 0.035 |
4170 | MCL1 | Dong_P3 | Human | Prostate | Tumor | 7.71e-09 | 3.69e-01 | 0.0278 |
4170 | MCL1 | Dong_P4 | Human | Prostate | Tumor | 5.20e-08 | 5.23e-01 | 0.0292 |
4170 | MCL1 | Dong_P5 | Human | Prostate | Tumor | 1.62e-22 | -5.27e-02 | 0.053 |
4170 | MCL1 | P7 | Human | Prostate | Tumor | 9.53e-12 | 1.66e+00 | -0.1025 |
4170 | MCL1 | P9 | Human | Prostate | Tumor | 1.95e-15 | 1.11e+00 | -0.0285 |
4170 | MCL1 | P10 | Human | Prostate | Tumor | 5.14e-12 | 1.18e+00 | -0.0902 |
4170 | MCL1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 4.52e-04 | 2.76e-01 | 0.1608 |
4170 | MCL1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.64e-23 | 9.00e-01 | 0.1621 |
4170 | MCL1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.34e-04 | 5.58e-01 | 0.1619 |
4170 | MCL1 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.04e-02 | 5.75e-01 | 0.159 |
4170 | MCL1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 8.17e-14 | 5.87e-01 | 0.1602 |
4170 | MCL1 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 2.65e-02 | 3.40e-01 | 0.1439 |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/MCL1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MCL1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MCL1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MCL1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MCL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MCL1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MCL1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MCL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MCL1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MCL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MCL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00621979 | Breast | Precancer | cellular response to chemical stress | 51/1080 | 337/18723 | 2.40e-10 | 2.34e-08 | 51 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:20012445 | Breast | Precancer | positive regulation of intrinsic apoptotic signaling pathway | 17/1080 | 58/18723 | 1.59e-08 | 1.12e-06 | 17 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00345999 | Breast | Precancer | cellular response to oxidative stress | 42/1080 | 288/18723 | 2.78e-08 | 1.79e-06 | 42 |
GO:20012356 | Breast | Precancer | positive regulation of apoptotic signaling pathway | 24/1080 | 126/18723 | 1.98e-07 | 1.01e-05 | 24 |
GO:19021758 | Breast | Precancer | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 11/1080 | 29/18723 | 2.95e-07 | 1.44e-05 | 11 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:19032019 | Breast | Precancer | regulation of oxidative stress-induced cell death | 16/1080 | 74/18723 | 3.80e-06 | 1.20e-04 | 16 |
GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
GO:00086318 | Breast | Precancer | intrinsic apoptotic signaling pathway in response to oxidative stress | 12/1080 | 45/18723 | 6.23e-06 | 1.76e-04 | 12 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PMID27744724-Compound-13 | | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PROCHLORPERAZINE | PROCHLORPERAZINE | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | SULFURETIN | SULFURETIN | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PMID27744724-Compound-22 | | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | CB7969312 | CHEMBL599255 | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | SJ000036432 | CHEMBL591135 | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | AMENTOFLAVONE | AMENTOFLAVONE | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | antagonist | 252166530 | VENETOCLAX | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LOMOFUNGIN | LOMOFUNGIN | |